It is possible new templates exist for this target since these models were created.
Available Structures
210 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| tau-microtubule structural ensemble based on CryoEM data |
Heteromer P02554; Q2XVP4; | 7×GDP; 7×GTP; 7×MG; | ||||
| Assess | ||||||
| tau-microtubule structural ensemble based on CryoEM data |
Heteromer P02554; Q2XVP4; | 7×GDP; 7×GTP; 7×MG; | ||||
| Assess | ||||||
| Model of synthetic tau (R2x4) bound to the microtubule |
Heteromer P02554; Q2XVP4; | 2×GDP; 1×GTP; 1×MG; | ||||
| Assess | ||||||
| Structure of tau peptide in complex with Tau5 antibody Fab fragment |
Heteromer A2NHM3; | 5×SO4; 4×NA; 1×PGE; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF ANTI-TAU ANTIBODY PT3 Fab+pT212/pT217-TAU PEPTIDE |
Heteromer | 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of anti-tau antibody dmCBTAU-28.1, double mutant (S32R, E35K) of CBTAU-28.1, in c… |
Heteromer | 1×CL; | ||||
| Assess | ||||||
| SOLUTION STRUCTURE OF PIN1 WW DOMAIN COMPLEXED WITH HUMAN TAU PHOSPHOTHREONINE PEPTIDE |
Heteromer Q13526; | |||||
| Assess | ||||||
| Crystal structure of human anti-tau antibody CBTAU-28.1 in complex with its tau peptide |
Heteromer | |||||
| Assess | ||||||
| X-RAY STRUCTURE OF THE FAB FRAGMENT OF THE ANTI TAU ANTIBODY RB86 IN COMPLEX WITH THE PHOSPHORYLATE… |
Heteromer | |||||
| Assess | ||||||
| Model of synthetic tau (four tandem repeats of first repeat sequence) bound to the microtubule |
Heteromer P02554; Q2XVP4; | 1×GTP; 1×MG; 2×GDP; | ||||
| Assess | ||||||
| Crystal structure of anti-tau antibody dmCBTAU-27.1, double mutant (S31Y, T100I) of CBTAU-27.1, in … |
Heteromer | 2×CL; | ||||
| Assess | ||||||
| Tau-S214 Phosphorylation Inhibits Fyn Kinase Interaction and Increases the Decay Time of NMDAR-medi… |
Heteromer P06241; | |||||
| Assess | ||||||
| Crystal structure of the human CHIP-TPR domain in complex with a 10mer acetylated tau peptide |
Heteromer Q9UNE7; | |||||
| Assess | ||||||
| Structure of the anti-ptau Fab (pT231/pS235_1) in complex with phosphoepitope pT231/pS235 |
Heteromer | 1×PO4; | ||||
| Assess | ||||||
| VHH Z70 mutant 3 in interaction with PHF6 Tau peptide |
Heteromer | |||||
| Assess | ||||||
| anti-pTau C21-ABS Fab in complex with pTau peptide |
Heteromer | |||||
| Assess | ||||||
| FAB CBTAU-22.1 IN COMPLEX WITH TAU PEPTIDE V1088-5 |
Heteromer | 1×GOL; | ||||
| Assess | ||||||
| VHH Z70 mutant 20 in interaction with PHF6 Tau peptide |
Heteromer | |||||
| Assess | ||||||
| Anti-TAU AT8 FAB with doubly phosphorylated TAU peptide |
Heteromer | 2×GOL; | ||||
| Assess | ||||||
| VHH Z70 mutant 1 in interaction with PHF6 Tau peptide |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of human anti-tau antibody CBTAU-24.1 in complex with its phosphorylated tau pept… |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of DC8E8 Fab in the complex with a 30-mer tau peptide at pH 6.5 |
Heteromer Q52L64; Q99LC4; | |||||
| Assess | ||||||
| Anti-TAU AT8 FAB with triply phosphorylated TAU peptide |
Heteromer | |||||
| Assess | ||||||
| Anti-TAU BIIB092 FAB with TAU peptide |
Heteromer A2NHM3; | |||||
| Assess | ||||||
| Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 8.5 |
Heteromer | 1×GLC; 4×PGE; | ||||
| Assess | ||||||
| Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS214 |
Heteromer P31947; | 2×CL; 4×MG; 6×CA; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 126B with 14-3-3sigma |
Heteromer P31947; | 2×CL; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 109B with 14-3-3sigma |
Heteromer P31947; | 1×49F; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
Heteromer P31947; | |||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
Heteromer P31947; | 1×49F; | ||||
| Assess | ||||||
| Fab/epitope complex of mouse monoclonal antibody C5.2 targeting a phospho-tau epitope. |
Heteromer | 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 6.5 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of Tau and acetylated tau peptide antigen |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of DC8E8 Fab in the complex with a 14-mer tau peptide at pH 7.5 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2e-I with 14-3-3sigma |
Heteromer P31947; | 7×NA; 2×D3W; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2c-I with 14-3-3sigma |
Heteromer P31947; | 2×CL; 1×MG; 2×NA; 2×D3K; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-I with 14-3-3sigma |
Heteromer P31947; | 5×NA; 2×D3Q; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-II with 14-3-3sigma |
Heteromer P31947; | 2×CL; 4×NA; 2×D4K; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2b with 14-3-3sigma |
Heteromer P31947; | 2×CL; 4×NA; 2×D4H; | ||||
| Assess | ||||||
| The complex structure of PHF core domain peptide of tau and antibody's Fab domain. |
Heteromer | |||||
| Assess | ||||||
| Fab/epitope complex of mouse monoclonal antibody 6B2 targeting a non-phosphorylated tau epitope. |
Heteromer | 1×PO4; | ||||
| Assess | ||||||
| Fab/epitope complex of human chimeric monoclonal antibody h4E6 targeting a phosphorylated tau epito… |
Heteromer | 1×GOL; 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 3.2d with 14-3-3sigma |
Heteromer P31947; | 2×CL; 2×MG; 8×NA; 2×60H; | ||||
| Assess | ||||||
| Fab/epitope complex of mouse monoclonal antibody 8B2 targeting a non-phosphorylated tau epitope. |
Heteromer | 3×GOL; 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS324 |
Heteromer P31947; | 4×MG; 2×CA; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 3.2e with 14-3-3sigma |
Heteromer P31947; | 2×CA; 2×CL; 2×NA; 2×60H; | ||||
| Assess | ||||||
| Acetylated tau repeat 1 and 2 fragment (AcR1R2) | homo-48-mer | |||||
| Assess | ||||||
| Structure of the Tau-PAM4 Type 1 amyloid fibril | homo-36-mer | |||||
| Assess | ||||||
| Structure of the Fmoc-Tau-PAM4 Type 4 amyloid fibril | homo-24-mer | |||||
| Assess | ||||||
| Structure of the Fmoc-Tau-PAM4 Type 3 amyloid fibril | homo-24-mer | |||||
| Assess | ||||||
| Alzheimer's disease paired-helical filament in complex with PET tracer GTP-1 | homo-23-mer | 23×Y9H; | ||||
| Assess | ||||||
| Structure of the Fmoc-Tau-PAM4 Type 2 amyloid fibril | homo-18-mer | |||||
| Assess | ||||||
| KVQIINKKLD, Structure of the amyloid spine from microtubule associated protein tau Repeat 2 | homo-18-mer | |||||
| Assess | ||||||
| VQIINK, Structure of the amyloid-spine from microtubule associated protein tau Repeat 2 | homo-18-mer | |||||
| Assess | ||||||
| First Intermediate Amyloid (FIA) - Tau | homo-16-mer | |||||
| Assess | ||||||
| RNA-induced tau amyloid fibril | homo-15-mer | |||||
| Assess | ||||||
| Tau - AD-LIA4 (tau intermediate amyloid) | homo-12-mer | |||||
| Assess | ||||||
| In vitro assembled tau filaments into Quadruple Helical Filaments type 1 (2c) | homo-12-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with MgCl2 and NaCl (14b) | homo-12-mer | |||||
| Assess | ||||||
| In vitro assembled 297-394 tau filaments, 700 rpm (34b) | homo-12-mer | |||||
| Assess | ||||||
| Globular glial tauopathy type 3 tau filament | homo-10-mer | |||||
| Assess | ||||||
| Globular glial tauopathy type 2 tau filament | homo-10-mer | |||||
| Assess | ||||||
| Argyrophilic grain disease type 2 tau filament | homo-10-mer | |||||
| Assess | ||||||
| Limbic-predominant neuronal inclusion body 4R tauopathy type 2 tau filament | homo-10-mer | |||||
| Assess | ||||||
| Conformation 1 of straight filament from primary age-related tauopathy brain | homo-10-mer | |||||
| Assess | ||||||
| Paired helical filament from primary age-related tauopathy brain | homo-10-mer | |||||
| Assess | ||||||
| Conformation 2 of straight filament from primary age-related tauopathy brain | homo-10-mer | |||||
| Assess | ||||||
| Paired helical tau filament extracted from GSS Patient brain tissue | tau filament from Gerstmann S… | homo-10-mer | |||||
| Assess | ||||||
| Tau Paired Helical Filament from Alzheimer's Disease incubated with EGCG for 3 hours | homo-10-mer | 10×KDH; | ||||
| Assess | ||||||
| Tau Paired Helical Filament from Alzheimer's Disease not incubated with EGCG | homo-10-mer | |||||
| Assess | ||||||
| Tau Paired Helical Filament from Alzheimer's Disease incubated 1 hr. with EGCG | homo-10-mer | |||||
| Assess | ||||||
| Paired helical filament extracted from PrP-CAA Patient brain tissue | homo-10-mer | |||||
| Assess | ||||||
| Pronase-treated paired helical filament in Alzheimer's disease brain | homo-10-mer | |||||
| Assess | ||||||
| Straight filament in Alzheimer's disease brain | homo-10-mer | |||||
| Assess | ||||||
| Straight tau filament extracted from PrP-CAA Patient brain tissue | tau filament | SF Tau | homo-10-mer | |||||
| Assess | ||||||
| Paired helical filament in Alzheimer's disease brain | homo-10-mer | |||||
| Assess | ||||||
| PHF Tau from Down Syndrome | homo-10-mer | |||||
| Assess | ||||||
| SF Tau from Down Syndrome | homo-10-mer | |||||
| Assess | ||||||
| Tau (297-391) in vitro untwisted fibril | homo-10-mer | |||||
| Assess | ||||||
| Temperature-dependent structures of tau aggregates | homo-10-mer | |||||
| Assess | ||||||
| KVQIINKKL, crystal structure of a tau protein fragment | homo-10-mer | |||||
| Assess | ||||||
| SVQIVY, Crystal Structure of a tau protein fragment | homo-10-mer | |||||
| Assess | ||||||
| Tau - AD-THF | homo-9-mer | |||||
| Assess | ||||||
| Tau - AD-MIA7 (tau intermediate amyloid) | homo-9-mer | |||||
| Assess | ||||||
| Tau - AD-MIA11 | homo-9-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with KCl (10a) | homo-9-mer | 18×CL; 18×K; | ||||
| Assess | ||||||
| Tau - CTE-LIA14 (tau intermediate amyloid) | homo-9-mer | |||||
| Assess | ||||||
| In vitro assembled tau filaments with MgSO4 and NaCl (15a) | homo-9-mer | |||||
| Assess | ||||||
| In vitro assembled 305-379 tau filaments (27a) | homo-9-mer | |||||
| Assess | ||||||
| MicroED structure of tau VQIVYK peptide at 1.1 A resolution | homo-9-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide VQIVYK from the second repeat region of tau (alternate poly… | homo-8-mer | |||||
| Assess | ||||||
| PHF tau filament from Kii ALS/PDC | homo-7-mer | |||||
| Assess | ||||||
| Tau Paired Helical Filament from Cellular Fraction of Alzheimer's disease brain | homo-7-mer | |||||
| Assess | ||||||
| Tau Paired Helical Filament from Extracellular Vesicles from Alzheimer's disease brain | homo-7-mer | |||||
| Assess | ||||||
| Doublet Tau Fibril from Corticobasal Degeneration Human Brain Tissue | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of TypeII tau filaments extracted from the brains of individuals with Corticobasa… | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with KCl (10b) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA11 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA2 | homo-6-mer | |||||
| Assess | ||||||
| Paired helical filament from sporadic Alzheimer's disease brain | homo-6-mer | |||||
| Assess | ||||||
| Straight filament from sporadic Alzheimer's disease brain | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA5 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau: AD-MIA1 | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-LIA7 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-LIA8 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-LIA6 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of in vitro PHF fibril | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-LIA5 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with ZnCl2 (11a) | homo-6-mer | |||||
| Assess | ||||||
| in vitro assembled tau filaments with structures like Paired Helical Filaments from Alzheimer's Dis… | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-LIA2 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 297-408 S396D S400D T403D S404D tau filaments (42a) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with NaHCO3 and NaCl (16a) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-PHF long crossover | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-PHF | homo-6-mer | |||||
| Assess | ||||||
| in vitro assembled 266/297 - 391 tau filaments with MgCl2 and NaCl (14a) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA15 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Chronic traumatic encephalopathy Type II Tau filament | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA5 | homo-6-mer | |||||
| Assess | ||||||
| Chronic traumatic encephalopathy Type I Tau filament | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA4 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA8 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA7 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Chronic traumatic encephalopathy tau filaments with PET ligand flortaucipir | homo-6-mer | 6×S9C; | ||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with LiCl (9a) | homo-6-mer | |||||
| Assess | ||||||
| Structure of Tau filaments Type II from Subacute Sclerosing Panencephalitis | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled tau filaments with structures like chronic traumatic encephalopathy type II (8a) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA3 | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA3 | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 297-394 tau filaments in PBS (35d) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA13 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA10 (intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA14 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA8 (intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| CTE typeIII tau filament | homo-6-mer | |||||
| Assess | ||||||
| CTE typeII tau filament from Guam ALS/PDC | homo-6-mer | |||||
| Assess | ||||||
| CTE typeIII tau filament from Guam ALS/PDC | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-type I (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| CTE tau intermediate amyloid (LIA-17) | homo-6-mer | |||||
| Assess | ||||||
| CTE type II (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA6 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA6 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with LiCl (9b) | homo-6-mer | |||||
| Assess | ||||||
| Paired helical tau filaments from high-spin supernatants of aqueous extracts from Alzheimer's disea… | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA7 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA5 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA4 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with MgSO4 and NaCl (15b) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA18 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - AD-MIA4 | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA9 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA1 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 300-391 tau filaments in PBS (36a) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA10 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| in vitro assembled 266/297 - 391 tau filaments with NaCl (8b) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with MgSO4 and NaCl (15c) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA3 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA13 (tau intermediate amyloid) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 0N4R tau filaments with phosphoserine (47a) | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of amyloid fibril formed by tau (297-391) | homo-6-mer | |||||
| Assess | ||||||
| Cofactor-free Tau 4R2N isoform | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266/297 - 391 tau filaments with CuCl2 (12a) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266-391 S356D tau filaments with NaCl (45a) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 266-391 S356D tau filaments with KCl (44a) | homo-6-mer | |||||
| Assess | ||||||
| In vitro assembled 258-391 tau filaments with sodium azide, (41a) | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of heparin-induced 2N3R tau filaments | homo-6-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide VQIVYK from the TAU protein in complex with orange G | homo-6-mer | 12×ZN; 6×ACY; 6×ORA; | ||||
| Assess | ||||||
| RQEFEV, crystal structure of the N-terminal segment RQEFEV from protein tau | homo-6-mer | |||||
| Assess | ||||||
| Argyrophilic grain disease type 1 tau filament | homo-5-mer | |||||
| Assess | ||||||
| Progressive supranuclear palsy tau filament | homo-5-mer | |||||
| Assess | ||||||
| Limbic-predominant neuronal inclusion body 4R tauopathy type 1a tau filament | homo-5-mer | |||||
| Assess | ||||||
| Limbic-predominant neuronal inclusion body 4R tauopathy type 1b tau filament | homo-5-mer | |||||
| Assess | ||||||
| Globular glial tauopathy type 1 tau filament | homo-5-mer | |||||
| Assess | ||||||
| Straight filament from Alzheimer's disease with PET ligand APN-1607 | homo-5-mer | |||||
| Assess | ||||||
| Paired helical filament from Alzheimer's disease with PET ligand APN-1607 | homo-5-mer | |||||
| Assess | ||||||
| Structure of Tau filaments Type I from Subacute Sclerosing Panencephalitis | homo-5-mer | |||||
| Assess | ||||||
| CTE typeI tau filament from Kii ALS/PDC | homo-5-mer | |||||
| Assess | ||||||
| CTE typeI tau filament from Guam ALS/PDC | homo-5-mer | |||||
| Assess | ||||||
| TypeII tau filament from Kii ALS/PDC | homo-5-mer | |||||
| Assess | ||||||
| Temperature-dependent structures of tau aggregates | homo-5-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide VQIVYK from the repeat region of Tau | homo-4-mer | |||||
| Assess | ||||||
| High-resolution map of tau filament from progressive supranuclear palsy (PSP) case 1 | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SH-SY5Y seeded with filaments from Alzheimer's Disease | homo-3-mer | |||||
| Assess | ||||||
| Singlet Tau Fibril from Corticobasal Degeneration Human Brain Tissue | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of TypeI tau filaments extracted from the brains of individuals with Corticobasal… | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SH-SY5Y seeded with filaments from corticobasal degeneration extracts | homo-3-mer | |||||
| Assess | ||||||
| Narrow Pick Filament from Pick's disease brain | homo-3-mer | |||||
| Assess | ||||||
| P301S Tau Filaments from the Brains of PS19 Transgenic Mouse Line | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SH-SY5Y seeded with filaments from corticobasal degeneration extracts (Type II) | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 258-391 tau filaments with phosphoglycerate, 700 rpm (39a) | homo-3-mer | |||||
| Assess | ||||||
| Tau - CTE-LIA6 (tau intermediate amyloid) | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 266-391 tau filaments in PBS (23a) | homo-3-mer | |||||
| Assess | ||||||
| Tau - CTE-MIA12 (tau intermediate amyloid) | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 258-391 tau filaments, 700 rpm (38a) | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of heparin-induced 2N4R tau snake filaments | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 258-391 tau filaments with heparan sulfate, 700 rpm (40a) | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 258-391 tau filaments with phosphoglycerate, 700 rpm (39a) | homo-3-mer | |||||
| Assess | ||||||
| In vitro assembled 244-391 tau filaments with Na2P2O7 (20a) | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of heparin-induced 2N4R tau jagged filaments | homo-3-mer | |||||
| Assess | ||||||
| Cryo-EM structure of heparin-induced 2N4R tau twister filaments | homo-3-mer | |||||
| Assess | ||||||
| Straight Filament from Alzheimer's Disease Human Brain Tissue | homo-2-mer | 2×GLY; | ||||
| Assess | ||||||
| Paired Helical Filament from Alzheimer's Disease Human Brain Tissue | homo-2-mer | 4×GLY; | ||||
| Assess | ||||||
| SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form II) | homo-2-mer | 2×PO4; 3×MPD; | ||||
| Assess | ||||||
| SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form I) | homo-2-mer | 3×PO4; | ||||
| Assess | ||||||
| SVQIVYK segment from human Tau (305-311) displayed on 54-membered macrocycle scaffold (form III) | homo-2-mer | 4×MPD; 1×PO4; | ||||
| Assess | ||||||
| Tau filaments extracted from human brain with the DeltaK281 mutation in MAPT | monomer | |||||
| Assess | ||||||
| Structure of Tau(267-312) bound to Microtubules | monomer | |||||
| Assess | ||||||
| Structure of Tau(254-290) bound to F-actin | monomer | |||||
| Assess | ||||||
| Structure of Tau(292-319) bound to F-actin | monomer | |||||
| Assess | ||||||
| Structure of Tau(254-268) bound to F-actin | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7mkf.1.H | monomer | 0.55 | 99.32 | |||
| Assess | ||||||
8 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 8q2j.1.A | monomer | 0.53 | 100.00 | ||
| Assess | ||||||
| Isoform 3 | 8q9a.1.A | monomer | 0.51 | 99.68 | ||
| Assess | ||||||
| Isoform 4 | 7nrt.1.H | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 5 | 6nwp.1.D | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 6 | 6nwp.1.D | monomer | 0.51 | 99.74 | ||
| Assess | ||||||
| Isoform 7 | 6nwp.1.D | monomer | 0.52 | 100.00 | ||
| Assess | ||||||
| Isoform 8 | 6nwp.1.D | monomer | 0.50 | 100.00 | ||
| Assess | ||||||
| Isoform 9 | 7mkf.1.H | monomer | 0.50 | 99.09 | ||
| Assess | ||||||